Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Charles Mcwherter Insider Profile
4 Followers
Charles Mcwherter, President of R&D at CymaBay Therapeutics, holds 10.00K shares in 89bio (Ticker: ETNB), holds 0.00 shares in CymaBay Therapeutics (Ticker: CBAY). Most recently, Charles Mcwherter Bought ― shares of 89bio on Dec 09, 2024 for an estimated value of 80.00K.
Charles Mcwherter CymaBay Therapeutics (CBAY)President of R&D
CymaBay Therapeutics (CBAY)
President of R&D
Ranked #15,592 out of 100,202 Corporate Insiders
Profitable Transactions
3 out of 5 Profitable Transactions
Average Return
+22.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Charles Mcwherter's holdings
Insider Roles
Director
Roles that Charles Mcwherter holds in companies
Most Profitable Insider Trade
Stock:
CymaBay Therapeutics
(CBAY)
(CBAY)
Rating:Informative Buy
Date:Apr 19, 2016 - Apr 19, 2017
Return:+73.20%
The most profitable trade made by Charles Mcwherter
Charles Mcwherter's Trading History
CymaBay Therapeutics
Mar 22, 2024
―
Uninformative Sell
―
$0.00
89bio
Dec 09, 2024
Director
Informative Buy
80.00K
$79.40K
List of latest transactions for each holding click on a transaction to see Charles Mcwherter's performance on stock
You May Also Like
Charles Mcwherter insider profile FAQ
What is the percentage of profitable transactions made by Charles Mcwherter?
The percentage of profitable transactions made by Charles Mcwherter is 60%.
What is the average return per transaction made by Charles Mcwherter?
The average return per transaction made by Charles Mcwherter is 22.80%.
What stocks does Charles Mcwherter hold?
Charles Mcwherter holds: CBAY, ETNB stocks.
What was Charles Mcwherter’s latest transaction?
Charles Mcwherter latest transaction was an Informative Buy of $80.00K.
What was Charles Mcwherter's most profitable transaction?
Charles Mcwherter’s most profitable transaction was an Informative Buy of CBAY stock on April 19, 2016. The return on the trade was 73.20%.
What is Charles Mcwherter's role in CymaBay Therapeutics?
Charles Mcwherter's role in CymaBay Therapeutics is President of R&D.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.